Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Owning CSL Ltd (ASX: CSL) shares over the past decade has been very rewarding, with good dividend growth and enormous capital growth. As shown on the chart below, the CSL share price has soared more than 200% in the past decade.

In my view, CSL may be the most impressive business on the ASX, with a market capitalisation of $100 billion. Its growth and global success are commendable.

Long-term shareholders are receiving much bigger dividends and are predicted to see even larger payments.

Let's have a look at how the CSL dividend could grow between now and the 2029 financial year.

Man holding Australian dollar notes, symbolising dividends.

Image source: Getty Images

This year, FY25

We're already close to halfway through the CSL 2025 financial year, so it won't be long before shareholders learn the FY25 interim dividend payment with the half-year result, which is expected in February 2025.

As for the annual dividend per share, UBS is currently forecasting that the CSL dividend could jump by 12% to US$2.96 per share. At the current CSL share price, that would represent a dividend yield of close to 1.7%.

UBS also considers the "possibility of a less vaccine-friendly US administration", which could impact CSL's vaccine business.

Next year, FY26

In the 2026 financial year, UBS is expecting CSL's profit to rise by more than 10%, and this can help the company's dividend rise too.

UBS is projecting that the CSL dividend could jump by another 12% to US$3.31 per share. That would represent a dividend yield of close to 1.9%. Not huge, but it's growing at a good pace.

After that, FY27

The 2027 financial year could see the business continue to grow its profit and dividend at a pleasing double-digit speed.

UBS projects that owners of CSL shares could receive an annual dividend per share of US$3.71, an increase of 12%. At the current valuation, that would represent a dividend yield of 2.1%.

Then, FY28

As an ASX healthcare share, it's quite possible that the company could deliver consistent profit growth over this period of time.

According to UBS, in the 2028 financial year, CSL could deliver a dividend increase of close to 12%, taking the annual payment to US$4.15. At the current CSL share price, that would represent a dividend yield of 2.35%.

Finally, FY29

The 2029 financial year is projected to be the best year of all – it could see yet another double-digit increase in percentage terms of both profit and dividend.

UBS forecasts that CSL's dividend could increase by another 12% in FY29 to US$4.65. At the current valuation, this payout would mean a dividend yield of 2.6%.

A 2.6% dividend yield isn't huge, but it shows how the dividend could scale upwards. Rising profit could also be exactly what investors want to see with CSL shares.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Happy healthcare workers in a lab.
Healthcare Shares

Telix share price leaping higher today on $3 billion US news

Investors are snapping up Telix shares on Monday following big US news.

Read more »

Four smiling young medics with arms crossed stand outside a hospital.
Healthcare Shares

Pro Medicus locks in 5-year, $37m Northwestern Medicine contract renewal

Pro Medicus has renewed its major contract with Northwestern Medicine, locking in higher fees and strengthened client ties for the…

Read more »

Rising healthcare ASX share price represented by doctor giving thumbs up
Healthcare Shares

Telix Pharmaceuticals announces US$40m Regeneron radiopharma deal

Telix Pharmaceuticals has announced a US$40m strategic collaboration with Regeneron for innovative radiopharmaceutical cancer therapies.

Read more »

Two health workers taking a break.
Healthcare Shares

It could be time to buy-low on this ASX small-cap stock according to brokers

This ASX healthcare stock keeps attracting positive ratings, with one broker now tipping a 268% rise.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Broker sees 26% upside in ASX healthcare share behind Chemist Warehouse

Morgans has just upgraded its rating on this ASX healthcare stock due to ongoing share price weakness.

Read more »

Woman using a pen on a digital stock market chart in an office.
Healthcare Shares

Why this ASX healthcare stock is surging while the market sinks on Middle East fears

Avita shares surge as a US government contract boosts sentiment again

Read more »

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
Healthcare Shares

Should you buy Telix shares after its big US news?

Is this milestone a reason to invest? Let's find out.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Up 31% in a month, why are Telix shares lifting off again on Friday?

ASX investors are piling into Telix shares today. But why?

Read more »